![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Active Filter(s):
Details:
Under the agreement, Biohaven and Highlightll will coordinate clinical development across global regions for BHV-8000 (previously TLL-041), an oral, brain-penetrant, dual inhibitor of TYK2 and JAK1 for the treatment of brain disorders.
Lead Product(s): BHV-8000
Therapeutic Area: Neurology Product Name: BHV-8000
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Biohaven Pharmaceuticals
Deal Size: $970.0 million Upfront Cash: $10.0 million
Deal Type: Licensing Agreement March 22, 2023